Key Takeaways J&J projects over $57B in 2025 Innovative Medicines sales with 5-7$25B in 2025 sales, which will rise to $31B by 2027.Both stocks have gained over 20% YTD, with AbbVie offering a higher dividend yield at around 3.2%.Johnson & Johnson (JNJ) and AbbVie (ABBV) are both pharma-driven healthcare giants with a strong presence in immunology, oncology and neuroscience areas. Other than that, J&J also has drugs for cardiovascular ...